Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression, Anxiety
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate clinical decision-making algorithms for (a) triaging to level of care and (b) adapting level of care in a low income, highly diverse sample of community college students at East Los Angeles College (ELAC). The target enrollment is 200 participants per year, for five years (N=1000). Participants are between the ages of 18 and 40 years and will be randomized into either symptom severity decision-making (SSD) or data-driven decision-making (DDD). Participants in each condition will be triaged to one of three levels of care, including self-guided online prevention, coach-guided online cognitive behavioral therapy, and clinician-delivered care. After initial triaging, level of care will be adapted throughout the entire time of the study enrollment. Participants will complete computerized assessments and self-report questionnaires as part of the study. The total length of participation is 40 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Self-Guided Online Prevention — An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
  • Behavioral: Coach-Guided Online Cognitive Behavioral Therapy — An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
  • Behavioral: Clinician-Delivered Psychological and Psychiatric Care — Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.

Primary Outcomes

  • Longitudinal trajectory of treatment adherence (Up to 40 weeks)
  • Baseline symptom severity for mental health (Baseline)
  • Longitudinal trajectory of symptom severity for mental health (Up to 40 weeks)
  • Baseline social, occupational, and home functioning (Baseline)
  • Baseline academic functioning (Baseline)
  • Longitudinal trajectory of social, occupational, and home functioning (Up to 40 weeks)
  • Longitudinal trajectory of academic functioning (Up to 40 weeks)
  • Suicide and self-harm (Up to 40 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-29
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Principal Investigators:
  • Michelle Craske, Ph.D (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
  • Kate Taylor, Ph.D (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
Contact Information
Study Contact:
Amelia Welborn, Ph.D.
916-202-5952
awelborn@mednet.ucla.edu
Alainna Wen, Ph.D.
AAWen@mednet.ucla.edu
Areli Vargas
VARGASA3@ELAC.EDU
East Los Angeles College
Interventions
  • Behavioral: Self-Guided Online Prevention — An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
  • Behavioral: Coach-Guided Online Cognitive Behavioral Therapy — An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
  • Behavioral: Clinician-Delivered Psychological and Psychiatric Care — Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
Study Locations (1 sites)
East Los Angeles College, Los Angeles, California 91754 United States
Eligibility Criteria
Inclusion Criteria: * Currently enrolled in the East Los Angeles College * Either uninsured or covered by California Medicaid * Own or have private access to internet to complete the assessments and online prevention and therapy programs Exclusion Criteria: * Unable to fully comprehend the consent form, respond adequately to screening questions, or maintain focus or to sit still during assessment * Diagnosed with disorders requiring more specialized care (e.g., psychotic disorder, severe eating disorder, severe substance use disorder, severe neurological disorder), or marked cognitive impairment * Currently treated by psychiatrist or psychologist during timeframe that the treatment is offered through STAND and is unwilling to fully transfer care to STAND
Conditions Pulmonary Arterial Hypertension, Connect...
Phase Not Applicable
Enrollment 170
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. All patients diagnosed with Group I Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) and Group IV Pulmonary Hypertension (PH) with CTD will be included. The purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • To characterize the clinical clinical course of Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) in a register of Mexican patients from the first visit and at every 6 months. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-12-15
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 170 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Principal Investigators:
  • Jose Luis Hernandez Oropeza, PhD (PRINCIPAL_INVESTIGATOR) - Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Contact Information
Study Contact:
Jose Luis Hernandez Oropeza, PhD
+52 55 5487 0900
elinternista@hotmail.com
Jose de Jesus Rodriguez Andoney, M.Sc.
+52 55 5487 0900
andoneyjjr@hotmail.com
Jose Luis Hernandez Oropeza, PhD
55 5487 0900
elinternista@hotmail.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Interventions
N/A
Study Locations (1 sites)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080 Mexico
Eligibility Criteria
Inclusion Criteria: * Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD) * Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation/perfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy. * Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology. * Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units Exclusion Criteria: * Patients who meet the criteria for another group of pulmonary hypertension (Groups II, III or V).
Conditions Chronic Obstructive Pulmonary Disease, E...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Chronic obstructive pulmonary disease (COPD) is a disease of the lungs that makes it hard for people to breath. Those with COPD spend considerably more time sitting and lying and less time performing physical activity than healthy individuals. Those who are the most sedentary have a greater risk of heart and blood vessel disease, which may lead to an early death. This project will investigate the effect of sitting still for 3 hours on blood vessel health in individuals with COPD. It will also investigate whether breaking up the amount of time patients sit with regular short bouts of walking (5 minutes each hour) at a comfortable pace chosen by the patient can have a positive effect on maintaining the health of their blood vessels. It is hypothesized that blood vessel health will be worse after 3 hours of sitting compared to when the sitting is broken up by short bouts of walking.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Microdoses of activity — Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.

Primary Outcomes

  • Change in superficial femoral artery endothelial function (Within 3 hours of sitting (Day1) or within 3 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-12
Completion: 2026-09-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Contact Information
Study Contact:
Neil Eves, PhD
250-807-9676
neil.eves@ubc.ca
Neil Eves, PhD
250-807-9676
neil.eves@ubc.ca
University of British Columbia
Interventions
  • Behavioral: Microdoses of activity — Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
Study Locations (1 sites)
University of British Columbia, Kelowna, British Columbia V1V2L2 Canada
Eligibility Criteria
Inclusion Criteria: Non-smoking (\>6 months) patients with stable moderate-to-severe COPD (post bronchodilator forced expired volume in 1 sec/forced vital capacity\<0.7 and \<lower limit of normal, 30%\<Forced Expired Volume in 1 sec\<80% predicted and exacerbation free for \>6 weeks) will be recruited for the study. Exclusion Criteria: 1. performing structured exercise training (or pulmonary rehabilitation) 2. have a history of deep vein thrombosis 3. are on anticoagulant medication 4. have advanced cardiac or cerebrovascular disease (i.e. heart failure, previous stroke or myocardial infarction) 5. have diabetes 6. have musculoskeletal contraindications that limit their ability to perform physical activity 7. vascular ultrasound measurements cannot be obtained.
Conditions Glaucoma, Glaucoma, Open-Angle, Optic Ne...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Repetitive, Transorbital Alternating Current Stimulation (rtACS) — Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina

Primary Outcomes

  • Change from baseline in visual field assessed by Humphrey Visual Field Index (VFI). (Baseline through 6 months)
  • Change from baseline in visual field assessed by Humphrey Mean Deviation (MD). (Baseline through 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-27
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Jeffrey L Goldberg, MD PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Study Team
650-497-5942
glaucomatrials@stanford.edu
Byers Eye Institute
Interventions
  • Device: Repetitive, Transorbital Alternating Current Stimulation (rtACS) — Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
Study Locations (1 sites)
Byers Eye Institute, Palo Alto, California 94303 United States
Eligibility Criteria
Inclusion Criteria: 1. Participant must be at least 18. 2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE). 3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false postivies do not exeed 20%. 4. In the opinion of the investigator the participant's eye pressure must be clinically stable. 5. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study. 6. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety. Exclusion Criteria: 1. Participant is unable to comply with study procedures or follow-up visits. 2. Participant has a history of ocular herpes zoster. 3. Participant has pathological nystagmus 4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa. 5. Participant has evidence of corneal opacification or lack of optical clarity. 6. Participant has uveitis or other ocular inflammatory disease. 7. Participant has any electric or electroinc implants such as a pacemaker. 8. Participant has acute conjunctivitis. 9. Participant has acute autoimmune disease. 10. Participant is pregnant or lactating. 11. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia. 12. Unresected brain tumors 13. Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable 14. Patients with any skin damage. 15. Children and comatose patients. 16. Patients with history of epileptic seizure within the last 10 years. 17. Patients with uncontrolled systemic hypertension or uncontrolled diabetes. 18. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation 19. Prior participation in a vision training/stimulation study in the last 12 months
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 252
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Every year there is an increase in people with diabetes all over the world. Because it is a disease associated with several comorbidities and is increasing, there is a need for more effective treatments. Lifestyle changes combined with medication are the best strategies for the treatment and reduction of comorbidities. Therefore, the present study posits the hypothesis that the integration of nutritional education groups into standard treatment, within a nutrition-specialized outpatient clinic, may yield additional enhancements in health parameters among patients diagnosed with type 2 diabetes. The driving force behind this research lies in the pursuit of more effective strategies to enhance glycemic control, diminish the risk of complications, and elevate the overall quality of life for these patients. Our motivation stems from a commitment to base our interventions on scientific evidence and strive towards meaningful improvements in diabetes management outcomes. A randomized clinical trial will be conducted with adult patients with a previous diagnosis of type 2 diabetes. Patients will be divided into two groups (intervention: nutritional education added the usual care; and control: usual care). The outcomes analyzed will be: glycemic control, lipid profile, body mass and dynapenia obesity, blood pressure values, eating behavior, diabetes complications and adherence to recommendations.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Operative group of nutrition education — The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.

Primary Outcomes

  • Change in baseline HbA1C at 4 months (From baseline to 4 months)
  • Change in baseline HbA1C at 8 months (From baseline to 8 months)
  • Change in baseline HbA1C at 12 months (From baseline to 12 months)
  • Change in diabetic retinopathy and baseline diabetic kidney disease at 12 months (From baseline to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-09-06
Completion: 2025-10-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital de Clinicas de Porto Alegre
Principal Investigators:
  • Jussara C De Almeida, PhD (PRINCIPAL_INVESTIGATOR) - Federal University of Rio Grande do Sul
Contact Information
Study Contact:
Jussara C De Almeida, PhD
+555133598410
jcalmeida@hcpa.edu.br
Jussara C De Almeida, PhD
+555133598410
jcalmeida@hcpa.edu.br
Hospital de Clinicas de Porto Alegre
Jussara C De Almeida, PhD
+555133598410
jcalmeida@hcpa.edu.br
Universidade Federal do Rio Grande do Sul
Interventions
  • Behavioral: Operative group of nutrition education — The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
Study Locations (2 sites)
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul 90035003 Brazil
Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul 90035003 Brazil
Eligibility Criteria
Inclusion Criteria: \- Adult patients with a previous diagnosis of type 2 diabetes mellitus Exclusion Criteria: * Patients with other types of diabetes * With HbA1C within the therapeutic target or with values greater than 12% * Severe neuropathy * Chronic kidney disease \[glomerular filtration rate \<30mL/min/1.73m²\] * Life expectancy \<6 months * Chemical dependence/alcoholism or use of antipsychotics * Autoimmune disease or chronic steroid use * Gastroparesis * Pregnant or lactating women * Patients who have had an Episode of Acute Coronary Syndrome (ACS) in the last 60 days * Wheelchair users * Cognitive, neurological or psychiatric condition
Conditions Breast Neoplasms
Phase NA
Enrollment 102
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study explores the feasibility of preoperative single-dose tumor-bed boost followed by oncoplastic breast-conserving surgery and ultra-hypofractionated postoperative radiotherapy in patients with early stage breast cancer. Patients less than 55 years old, who are diagnosed with breast cancer and are eligible to recieve breast-conserving surgery are enrolled. Patients who are older than 55 years, with suspected regional lymph node metastasis are excluded. The primary end point are the acute toxicities within 4 weeks after adjuvant radiation. The secondary endpoints are oncologic outcomes, surgical complications within 30 days, late toxicities, patients' quality of life and cosmetic outcomes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5) — Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.

Primary Outcomes

  • The rate of patients who develop radiation-associated acute toxicity (≥ 2 degree) (until 4 weeks of postoperative radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-21
Completion: 2028-07
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigators:
  • Jing Wang, M.D. (STUDY_CHAIR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Shu-lian Wang, M.D. (STUDY_CHAIR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Hao Jing, M.D. (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Hao Dong, M.D.
+861087787678
howelu1349@hotmail.com
Hao Jing, M.D.
+861087788281
owletskim@163.com
Hao Jing, M.D.
+861087788281
owletskim@163.com
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Radiation: Preoperative MRI-guided tumor-bed boost and postopreative ultra-hypofractionated radiotherapy (26 Gy/5.2Gy/5) — Preoperative tumor-bed boost was performed under MRI Linac, and a single dose of 10Gy is prescribed. The postoperative radiotherapy of 26Gy/5.2Gy/5 fractions is within 6 weeks following surgery. Adjuvant chemotherapy, targeted therapy and endocrine therapy are initiated no more than 12 weeks after surgery.
Study Locations (1 sites)
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with invasive breast cancer; 2. cN0 based on clinical physical examination combined with at least two imaging tests, or axillary fine-needle biopsy proved pN0; 3. Patients who plan to receive breast-conserving surgery or breast-conserving oncoplastic surgery; 4. No distant metastasis; 5. The primary tumour\> 5mm from the skin, without invasion of the ribs or intercostal muscles; 6. No neoadjuvant systemic therapy; 7. Patients who can tolerate MRI; 8. Life expectancy ≥5 years; 9. Organ function is fine (Hemoglobin ≥100g/L, leukocyte ≥2×109/L, neutrophil ≥1×109/L, platelet ≥80×109/L; Creatinine 1.5 mg/dl or less; Alanine aminotransferase/aspartate aminotransferase ≤2.5×UNL.); 10. Patients are willing to cooperate to follow up; 11. Patients should sign the informed consent; 12. Women of childbearing age need effective contraception. Exclusion Criteria: 1. Concurrent active connective tissue disease; 2. Patients who had radiotherapy to the ipsilateral breast or adjacent areas before; 3. Other malignancies, which affect pateint life expectancy (except adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder neoplasms (no more than T1)); 4. Severe comorbidities or active disease (Poorly controlled heart disease: New York Classification of Cardiac Function ≥ Grade 2, active coronary heart disease, unstable angina pectoris, arrhythmia requiring medical treatment/persistent refractory hypertension; Myocardial infarction, stroke within six months; Poorly controlled diabetes persists. Fasting blood glucose ≥ 10mmol/L, 2 hours postprandial blood glucose ≥ 13 mmol/L. Poorly controlled psychosis develops or worsens within six months; Active infection; Positive for antibodies to HIV).
Conditions Glucose Intolerance After a Recent Histo...
Phase PHASE3
Enrollment 252
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Semaglutide Pen Injector — maintenance dose of 1mg SC once weekly
  • Drug: Semaglutide placebo — maintenance dose of 1mg SC once weekly

Primary Outcomes

  • Development of T2DM (by 160 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-09-14
Completion: 2030-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Collaborators: University Hospital, Antwerp, Universitair Ziekenhuis Brussel, General Hospital Groeninge, Vitaz, Centre Hospitalier Universitaire de Liege, Erasme University Hospital, Centre Hospitalier Mouscron, Jan Yperman Ziekenhuis, AZ Turnhout, AZ Sint-Lucas Brugge, Ziekenhuis aan de Stroom, Onze Lieve Vrouw Hospital
Contact Information
Study Contact:
Katrien Benhalima, MD PhD
16340614
katrien.benhalima@uzleuven.be
Katrien Wierckx
AZORG
Niels Bochanen
UZA
Interventions
  • Drug: Semaglutide Pen Injector — maintenance dose of 1mg SC once weekly
  • Drug: Semaglutide placebo — maintenance dose of 1mg SC once weekly
Study Locations (13 sites)
AZORG, Aalst, Belgium
UZA, Antwerp, Belgium
ZAS, Antwerp, Belgium
AZ St Jan Brugge, Bruges, Belgium
Erasme, Brussels, Belgium
UZ Brussel, Brussels, Belgium
Jan Yperman, Ieper, Belgium
AZ Groeninge Kortrijk, Kortrijk, Belgium
UZ Leuven, Leuven, Belgium
CHU de Liège, Liège, Belgium
Eligibility Criteria
Eligible participants are women aged ≥18 years, with a history of GDM diagnosed according to the 2013 WHO criteria (at 24-32 weeks gestation or \<24 weeks for early GDM). Participants must have prediabetes diagnosed between 6 weeks and 12 months postpartum according to ADA criteria (FPG 5.6-6.9 mmol/L, 2-hour OGTT glucose 7.8-11.0 mmol/L and/or HbA1c 39-46 mmol/mol \[5.7-6.4%\]). Additional inclusion criteria include cessation of breastfeeding, no intention to become pregnant within the next year, use of effective contraception and no use of medication affecting glucose metabolism. Written ICF is obtained prior to any study-related procedures. Exclusion criteria include established diabetes, presence of autoantibodies suggestive of type 1 diabetes, normal glucose tolerance, history of pancreatitis, previous bariatric surgery or planned surgery within two years, unable to understand and speak Dutch, French or English and current pregnant or planning to become pregnant within one year after participating in the study.
Conditions Cancer, Tyrosine Kinase Mutation, Breast...
Phase Not Applicable
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Interview (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-24
Completion: 2026-06-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Collaborators: Social Sciences and Humanities Research Council of Canada
Contact Information
Study Contact:
Edith Pituskin, PhD
7804328221
pituskin@ualberta.ca
Meredith Porter Hogg, MN
lngeviti@ualberta.ca
Edith Pituskin, PhD
7804328221
pituskin@ualberta.ca
Edith Pituskin
Interventions
N/A
Study Locations (1 sites)
Edith Pituskin, Edmonton, Alberta T6G 1C9 Canada
Eligibility Criteria
Inclusion Criteria: taking chronic targeted anti-cancer agents - Exclusion Criteria: \-
Conditions Non-communicable Diseases (NCDs)
Phase Not Applicable
Enrollment 17500
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This ComBaCaL cohort study is to assess the impact of community-based, lay-led chronic disease screening and care interventions in rural Lesotho. It aims to establish a prospective research and service delivery platform in rural Lesotho that is managed by eHealth-supported Chronic Care Village Health Worker (CC-VHWs) providing regular chronic disease screening, monitoring and referral services. The implementation outcomes of the cohort as well as the effect of the cohort activities on disease-specific care cascades will be assessed. Subsequently, nested trials to assess the effectiveness of specific chronic disease control interventions will be developed. Measurements and data entry will be conducted by CC-VHWs. The CC-VHWs will be equipped with the essential tools required for chronic disease monitoring in the community (i.e. BP machines, scales, measuring band, glucometers, and urine dipsticks). They will undergo a theoretical and practical training covering all aspects required for correct data collection and chronic disease screening, diagnosing, referral and counselling services. At every visit, the CC-VHW will screen participants for warning signs and symptoms (i.e. shortness of breath, severe headache, chest pain, new-onset confusion, impaired consciousness, severely impaired general state of health) and refer participants to the closest health centre in case of any danger-sign. The CC-VHWs will be continuously monitored and supervised by health centre nurses of the respective village's catchment area, mainly through direct interaction during monthly VHW meetings and by CC nurses through field visits, remote interaction via phone calls or messages sent via the ComBaCaL app and through direct contact during the monthly VHW meetings at the health centre. The CC-VHWs are embedded within the Lesotho MoH VHW program and may during the project period be trained and equipped to provide further routine services in their communities.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Screening coverage (At baseline)
  • Disease awareness (At baseline)
  • Linkage to care (Up to 3 years after enrolment)
  • Engagement in care (Up to 3 years after enrolment)
  • Disease control level (Up to 3 years after enrolment)
  • Occurrence of clinically relevant events (number) (Up to 3 years after enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-22
Completion: 2027-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 17500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Collaborators: Swiss Agency for Development and Cooperation, The World Diabetes Foundation, SolidarMed
Principal Investigators:
  • Niklaus Labhardt, Prof. Dr. med. (PRINCIPAL_INVESTIGATOR) - Division of Clinical Epidemiology, University Hospital Basel, University of Basel
  • Alain Amstutz, MD (PRINCIPAL_INVESTIGATOR) - Division of Clinical Epidemiology, University Hospital Basel, University of Basel
Contact Information
Study Contact:
Niklaus Labhardt, Prof. Dr. med.
+41 79 870 18 59
niklaus.labhardt@usb.ch
Alain Amstutz, MD
+41 79 489 94 48
alain.amstutz@usb.ch
Irene Ayakaka, MD PhD
+266 28325172
Solidarmed Lesotho
Interventions
N/A
Study Locations (2 sites)
Solidarmed Lesotho, Maseru, Lesotho
Division of Clinical Epidemiology, University Hospital Basel, University of Basel, Basel, 4001 Switzerland
Eligibility Criteria
Inclusion Criteria village level: * Village size of 40 to 100 households * Village consent obtained from village chief * Possibility to identify or recruit a CC-VHW from the village population meeting the following requirements which are largely in line with the criteria of the Lesotho VHW Program Policy: o Criteria of the Lesotho Village Health Program Policy: * Having primary residence in the village (according to village chief) * Having a proven record of trustworthiness in the resident village * Having proven ability to maintain confidentiality on public matters * Being aged between 20 and 50 years * Being able to provide written reports and being able to do basic mathematical calculations * Having at least educational level equivalent to high school leaving certificate (Junior Certificate) o Additional ComBaCaL criteria: * Having the ability and willingness to work with a tablet-based eHealth tool * Having good social and communication skills * Having the ability and willingness to interact with health professionals and the village population * Being able to speak, understand and write in English- * Having successfully completed the ComBaCaL CC-VHW training including final assessment Inclusion criteria individual level: * Having primary residence in the village (self-reported at time of enrolment) * Being able and willing to consent to participation or in case of individuals aged below 18
Conditions Preeclampsia, Microvascular Function
Phase EARLY_PHASE1
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia is a pregnancy disorder affecting \~5-10% of pregnancies in the United States. Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. Low dose aspirin (LDA; 75-150mg/daily) is currently the most effective and clinically accepted therapy for reducing preeclampsia prevalence in women at high risk for developing the syndrome. The purpose of this study is to interrogate the mechanisms by which LDA therapy mitigates persistent vascular dysfunction in postpartum women who have had preeclampsia. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had a history of preeclampsia. As a compliment to these measurements, they also draw blood from the subjects and isolate the inflammatory cells.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Acetylcholine — acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
  • Drug: Endothelin-1 — endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.

Primary Outcomes

  • microvascular endothelial function (at the study visit, an average of 4 hours)
  • microvascular endothelin-1-mediated constriction (at the study visit, an average of 4 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-01-03
Completion: 2027-07-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anna Stanhewicz, PhD
Contact Information
Study Contact:
Anna Reid-Stanhewicz, PHD
319-467-1732
anna-stanhewicz@uiowa.edu
Anna Stanhewicz, PhD
319-467-1732
anna-stanhewicz@uiowa.edu
University of Iowa
Interventions
  • Drug: Acetylcholine — acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
  • Drug: Endothelin-1 — endothelin-1, endothelin-1 + BQ-788 (endothelin receptor type B-inhibitor), and endothelin-1 + BQ-123 (endothelin receptor type A-inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelin-mediated constriction and the role of the receptor subtypes in this response.
Study Locations (1 sites)
University of Iowa, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion: * 18 years or older, * 12 weeks to 5 years postpartum * and one of the following: 1. women who had a normal pregnancy and did not use low does aspirin (LDA) during pregnancy, 2. women who had a normal pregnancy and used LDA during pregnancy, 3. women who had preeclampsia and did not use LDA during pregnancy, 4. women who had preeclampsia and used LDA during pregnancy. Exclusion: * current daily aspirin use, * skin diseases, * current tobacco use, * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * current pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs.
Conditions Primary Open Angle Glaucoma
Phase NA
Enrollment 78
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device — 360 degree microcatheterization and viscodilation of Schlemm's canal
  • Procedure: Cataract surgery — Cataract surgery alone

Primary Outcomes

  • Reduction in mean Intraocular Pressure (IOP) at 12 months compared to baseline (12 months)
  • Reduction in number of glaucoma medications at 12 months compared to baseline (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-09-08
Completion: 2027-07
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 78 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Eye, Inc.
Collaborators: Nova Eye Medical GmbH
Principal Investigators:
  • Norbert Koerber, MD (PRINCIPAL_INVESTIGATOR) - Augencentrum Köln Ophthalmology
Contact Information
Study Contact:
Mike Pickrel
800-391-2316
MPickrel@Nova-Eye.com
Morgan Micheletti, MD
Berkeley Eye Center
Karl Mercieca, MD
University of Bonn Eye Clinic
Interventions
  • Device: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device — 360 degree microcatheterization and viscodilation of Schlemm's canal
  • Procedure: Cataract surgery — Cataract surgery alone
Study Locations (4 sites)
Berkeley Eye Center, Sugar Land, Texas 77478 United States
University of Bonn Eye Clinic, Bonn, Germany
Augencentrum Köln Ophthalmology, Cologne, Germany
St. Johannes Hospital, Dortmund, Germany
Eligibility Criteria
Inclusion Criteria: * Mild to moderate, primary open angle glaucoma * Characteristics consistent with mild to moderate glaucoma * Use of 1 - 4 ocular hypotensive medications at the Screening exam and meets the IOP (intraocular pressure) criteria * Visually significant cataract Exclusion Criteria: Any of the following prior treatments for glaucoma (study eye): * Laser Trabeculoplasty * Endocyclophotocoagulation (ECP) or Micropulse laser * iStent or iStent Inject * Hydrus Microstent * Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma drainage device/valve. * Prior canaloplasty (ab-interno and ab-externo) * Prior goniotomy, or trabeculotomy (ab-interno or ab-externo) * Suprachoroidal stent (e.g., Cypass, iStent Supra, XEN, MINIject) * Concurrent IOP-lowering procedure other than use of the iTrackTM Advance canaloplasty device at the time of surgery (e.g., ECP, CPC, etc.) * Previous treatment with iTrack (Note: permitted if fellow eye only was treated) * Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma
Conditions BPD - Bronchopulmonary Dysplasia, Pulmon...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety and explore the PK/PD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post-surgical NEC and BPD±PH.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: L-Citrulline — Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).

Primary Outcomes

  • Safety of oral L-Citrulline administration (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-01
Completion: 2028-03
Eligibility
Age: 1 Month and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hospital for Sick Children
Principal Investigators:
  • Estelle Gauda, MD (PRINCIPAL_INVESTIGATOR) - Division Head, Division of Neonatology
Contact Information
Study Contact:
Rachana Patel, MSc, CCRP
+1(416)-813-7654
rachana.patel@sickkids.ca
Jeffrey Antwi
+1(416-)813-7654
jeffrey.antwi@sickkids.ca
Principal investigator
estelle.gauda@sickkids.ca
The Hospital For Sick Children
Interventions
  • Dietary Supplement: L-Citrulline — Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
Study Locations (1 sites)
The Hospital For Sick Children, Toronto, Ontario M5G 1X8 Canada
Eligibility Criteria
Arm 1: BPD±PH: Inclusion Criteria: * Born ≤ 30 weeks at birth * Post-menstrual age (PMA) ≥ 32 weeks * Echocardiographic evidence of PH for infants with BPD+PH. * On invasive or non-invasive ventilation with RSS \>2.0 for \>12hours/day for at least 48 hours as an early predictor of evolving BPD * Informed written consent (parents/substitute decision maker) Exclusion Criteria * Congenital Heart Disease \[Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)\] * Infants with pulmonary vein stenosis * Concurrent sepsis with hemodynamic instability * Infants considered likely to die within next 7 days * Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant Arm 2: surgical NEC Inclusion Criteria: * Born ≤ 30 weeks at birth * Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery) * Tolerating 50 ml/kg/day of enteral feeds * Informed written consent (parents/substitute decision maker) * Considered medically stable by clinical team Exclusion Criteria * Congenital heart disease (except small ASD, small VSD and non hsPDA) * Pulmonary vein stenosis * Concurrent sepsis with hemodynamic instability * Likely to die within next 7 days * Other condition significantly affecting pulmonary function independent of prematurity or NEC